Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer FSME-IMMUN / TicoVac by Year
FSME-IMMUN / TicoVac (tick-borne encephalitis vaccine) — International revenues ($M) ($M)
Pfizer FSME-IMMUN / TicoVac: $316M in FY2025, up 14.1% from a year earlier. That is the highest of the 10 years on record here.
Where the FY2025 figure comes from
“|| FSME-IMMUN/TicoVac | 319 | 280 | 14% | 10% | 3 | 3 | 13% | 316 | 277 | 14% | 10%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up FSME-IMMUN / TicoVac
Cite this data
StockData. (2026). Pfizer FSME-IMMUN / TicoVac ($M), annual FY2016–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/fsme-intl
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.